hydroxyindoleacetic acid has been researched along with Alzheimer Disease in 101 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A disturbed sleep-wake rhythm is common in Alzheimer disease (AD) patients and correlated with decreased melatonin levels and a disrupted circadian melatonin rhythm." | 7.72 | Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. ( Feenstra, MG; Fischer, DF; Liu, RY; Ravid, R; Swaab, DF; Toranõ, JS; Van Kan, HJ; Wu, YH; Zhou, JN, 2003) |
| "In this study we investigated the cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in Alzheimer (AD) patients (n=75), patients with mild cognitive impairment (MCI, n=9) and patients with depression (n=7)." | 7.72 | 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. ( Ganzer, S; Müller-Thomsen, T; Stuerenburg, HJ, 2004) |
| "Cerebrospinal fluid (CSF) concentration of beta-endorphin (beta-Ep), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) was measured in 15 patients with dementia of the Alzheimer type (DAT) and in 16 patients suspected of having Binswanger's disease (BD) by MRI, which sometimes resembles DAT clinically." | 7.68 | CSF beta-endorphin, HVA and 5-HIAA of dementia of the Alzheimer type and Binswanger's disease in the elderly. ( Chiba, T; Hagiwara, M; Kaieda, R; Kitahama, T; Lee, S; Nagazumi, A; Terashi, A, 1990) |
| "Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in the sixth, 13th, and 20th milliliters of CSF in patients with dementia of the Alzheimer's type (DAT) and Parkinson's disease (PD), and in an aliquot of CSF in controls." | 7.67 | Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. ( Albert, ML; Bird, ED; Direnfeld, LK; Freedman, M; Langlias, PJ; Volicer, L, 1985) |
| "Serotonin (5-HT), its precursor 5-hydroxytryptophan (5-HTP), and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured in the cerebrospinal fluid (CSF) of 14 patients with dementia of the Alzheimer type (DAT) and in nine controls by high-performance liquid chromatography with a novel multisensor coulometric detection system." | 7.67 | Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. ( Gamache, PH; Langlais, PJ; Mark, KA; Matson, WR; Volicer, L, 1985) |
| "It is concluded that in severe forms of senile dementia of Alzheimer type, there is a decrease in the levels of HVA and 5-HIAA in CSF which may reflect a decreased turnover of dopamine and serotonin." | 5.26 | Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type. ( MacDonald, E; Rekonen, M; Riekkinen, PJ; Soininen, H, 1981) |
| "Five patients with the early-onset form of Alzheimer disease (AD) received GM1 ganglioside by continuous injection into the frontal horns of the lateral ventricles for a period of 12 months." | 5.10 | Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. ( Bråne, G; Karlsson, I; Lekman, A; Ramström, I; Svennerholm, L; Wikkelsö, C, 2002) |
| "A disturbed sleep-wake rhythm is common in Alzheimer disease (AD) patients and correlated with decreased melatonin levels and a disrupted circadian melatonin rhythm." | 3.72 | Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. ( Feenstra, MG; Fischer, DF; Liu, RY; Ravid, R; Swaab, DF; Toranõ, JS; Van Kan, HJ; Wu, YH; Zhou, JN, 2003) |
| "In this study we investigated the cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in Alzheimer (AD) patients (n=75), patients with mild cognitive impairment (MCI, n=9) and patients with depression (n=7)." | 3.72 | 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. ( Ganzer, S; Müller-Thomsen, T; Stuerenburg, HJ, 2004) |
| "Cerebrospinal fluid (CSF) concentration of beta-endorphin (beta-Ep), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) was measured in 15 patients with dementia of the Alzheimer type (DAT) and in 16 patients suspected of having Binswanger's disease (BD) by MRI, which sometimes resembles DAT clinically." | 3.68 | CSF beta-endorphin, HVA and 5-HIAA of dementia of the Alzheimer type and Binswanger's disease in the elderly. ( Chiba, T; Hagiwara, M; Kaieda, R; Kitahama, T; Lee, S; Nagazumi, A; Terashi, A, 1990) |
| "Patients with Alzheimer disease (AD, onset less than 65 years of age, n = 13) and senile dementia of the Alzheimer type (SDAT, onset greater than or equal to 65 years of age, n = 28) were investigated for cerebrospinal fluid (CSF) content of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxy-phenylglycol (MHPG) and compared with a group of controls (n = 26)." | 3.67 | Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. ( Blennow, K; Bråne, G; Gottfries, CG; Karlsson, I; Lekman, A; Parnetti, L; Svennerholm, L; Wallin, A, 1989) |
| "Serotonin (5-HT), its precursor 5-hydroxytryptophan (5-HTP), and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured in the cerebrospinal fluid (CSF) of 14 patients with dementia of the Alzheimer type (DAT) and in nine controls by high-performance liquid chromatography with a novel multisensor coulometric detection system." | 3.67 | Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. ( Gamache, PH; Langlais, PJ; Mark, KA; Matson, WR; Volicer, L, 1985) |
| " Lumbar cerebrospinal fluid (CSF) neurotransmitter metabolite levels for homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were determined in patients with schizophrenia and Alzheimer's disease." | 3.67 | Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations. ( Davis, KL; Losonczy, MF; Mohs, RC, 1984) |
| "Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in the sixth, 13th, and 20th milliliters of CSF in patients with dementia of the Alzheimer's type (DAT) and Parkinson's disease (PD), and in an aliquot of CSF in controls." | 3.67 | Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. ( Albert, ML; Bird, ED; Direnfeld, LK; Freedman, M; Langlias, PJ; Volicer, L, 1985) |
| " Pharmacokinetic investigations showed that the oral bioavailability of tacrine was low and greatly varying between subjects." | 2.67 | Clinical experiences and biochemical findings with tacrine (THA). ( Ahlin, A; Hassan, M; Junthé, T; Nybäck, H, 1993) |
| "Patients with Alzheimer's disease (AD) have been reported to have a rate of nonsuppression on the dexamethasone suppression test (DST) comparable to that of patients with major depression." | 2.38 | The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. ( Hill, JL; Lawlor, BA; Martinez, R; Mellow, AM; Molchan, SE; Sunderland, T, 1990) |
| "Abnormalities found in senile or presenile dementia were not always parallel to the age-related changes." | 2.38 | Senile dementia and presenile dementia. ( Nakamura, S, 1990) |
| "Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are the two most common causes of dementia." | 1.46 | Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study. ( Hatsuta, H; Kanemaru, K; Komiya, T; Morimoto, S; Murayama, S; Nakano, Y; Nishina, Y; Saito, Y; Sengoku, R; Sumikura, H; Takao, M; Uchino, A, 2017) |
| "Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are present during the disease course of nearly all AD patients and consist of psychosis, agitation/aggression, and depression, among others." | 1.40 | Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. ( Aerts, T; De Deyn, PP; Engelborghs, S; Van Dam, D; Vermeiren, Y, 2014) |
| "Depression and aggression in Alzheimer's disease (AD) are 2 of the most severe and prominent neuropsychiatric symptoms (NPS)." | 1.40 | Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. ( Aerts, T; De Deyn, PP; Engelborghs, S; Van Dam, D; Vermeiren, Y, 2014) |
| "Given that carriers of certain Alzheimer's disease (AD)-related PS-1 variants are predisposed to clinical depression and that depression has been historically associated with the mitochondrial enzyme, monoamine oxidase-A (MAO-A), we investigated cortical MAO-A function in the AD-related PS-1(M146V) knock-in mouse." | 1.38 | Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex. ( Baker, GB; Cao, X; Chlan-Fourney, J; Gabriel, GG; Mousseau, DD; Nazarali, AJ; Pennington, PR; Rui, L; Wei, Z, 2012) |
| "Delirium is a complex neuropsychiatric syndrome with an acute onset and fluctuating course." | 1.33 | Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium. ( Engelhart, MJ; Fekkes, D; Tiemeier, H; van der Cammen, TJ, 2006) |
| "Subjects with Alzheimer type dementia (AD), vascular dementia (VD), and controls without dementia (C) were investigated." | 1.30 | Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. ( Wada, H, 1998) |
| " In the second phase of this study the same 12 PDD patients were treated with GAP at a daily dosage of 250 lipasemic-releasing units for a period of 1 month and it was found that all four biochemical parameters shifted towards normal values during therapy with the changes in CSF 5-hydroxy-indole acetic acid levels attaining statistical significance." | 1.29 | Glycosaminoglycan polysulfate in primary degenerative dementia. Pilot study of biologic and clinical effects. ( Ban, TA; Parnetti, L; Senin, U, 1995) |
| "These neurons are affected in Alzheimer's disease (AD) in several ways: serotonin is decreased in axon terminals, serotonin neurons accumulate neurofibrillary protein, and these neurons are lost in AD brains." | 1.28 | Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease. ( Burke, WJ; Chung, HD; Haring, JH; Joh, TH; Marshall, GL; Park, DH, 1990) |
| "Psychosis was associated with significantly increased densities of senile plaques and neurofibrillary tangles in the prosubiculum and middle frontal cortex, respectively, with trends toward increased densities of these lesions in the other areas examined." | 1.28 | Neuropathologic and neurochemical correlates of psychosis in primary dementia. ( Claassen, D; Kopp, U; Martinez, AJ; Moossy, J; Rao, G; Rosen, J; Zubenko, GS, 1991) |
| "In a prospective study of patients with Parkinson's disease we found a continuum of cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations." | 1.28 | Coexisting dementia and depression in Parkinson's disease. ( Coté, L; Mayeux, R; Rosenstein, R; Sano, M; Stern, Y; Williams, J, 1989) |
| "Patients with hypoxic encephalopathy consisted of 5 with apallic syndrome and one patient with Lance-Adams syndrome." | 1.28 | [Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases]. ( Fukuda, H; Hara, K; Kameyama, M; Nakamura, S; Udaka, F, 1989) |
| "In contrast to senile dementia of Alzheimer's type SLI was not correlated with dementia scores but with motor disease progression." | 1.28 | Parkinson's disease and dementia: clinical and neurochemical correlations. ( Cramer, H; Strittmatter, MM, 1992) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| "Patients who had Alzheimer's disease-senile dementia of the Alzheimer type (AD/SDAT) or multi-infarct dementia (MID) were compared with a group of controls." | 1.27 | Dementia of the Alzheimer type and multi-infarct dementia: a clinical description and diagnostic problems. ( Adolfsson, R; Bucht, G; Winblad, B, 1984) |
| "The nbM from patients with Alzheimer's disease showed significant decreases in both spiperone binding and in the levels of dopamine and serotonin but no decrease in either tyrosine or tryptophan levels." | 1.27 | Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis. ( Markesbery, WR; Slevin, JT; Sparks, DL, 1986) |
| "Values for serotonergic markers in Alzheimer's disease samples did not show correlations with rating of the severity of dementia, indices of cholinergic innervation, or senile plaque and cortical pyramidal neurone loss." | 1.27 | Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. ( Benton, JS; Bowen, DM; Francis, PT; Mann, DM; Neary, D; Palmer, AM; Sims, NR; Snowden, JS, 1987) |
| "5-Hydroxyindoleacetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower than in control subjects." | 1.27 | Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. ( Atack, JR; Beal, MF; Daly, E; Friedland, RP; Kaufman, S; Kaye, JA; May, C; Milstien, S; Rapoport, SI; Sweeney, DL, 1988) |
| "It is concluded that in severe forms of senile dementia of Alzheimer type, there is a decrease in the levels of HVA and 5-HIAA in CSF which may reflect a decreased turnover of dopamine and serotonin." | 1.26 | Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type. ( MacDonald, E; Rekonen, M; Riekkinen, PJ; Soininen, H, 1981) |
| "The diagnosis of Alzheimer's disease (13 patients) and Pick's disease (4 patients) has been made on clinical and radiological grounds." | 1.26 | [Cerebral metabolism of dopamine and of serotonin during Alzheimer and Pick's diseases. Dynamic study by the test using probenecid]. ( Chazot, G; Guard, O; Renaud, B, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 51 (50.50) | 18.7374 |
| 1990's | 29 (28.71) | 18.2507 |
| 2000's | 7 (6.93) | 29.6817 |
| 2010's | 11 (10.89) | 24.3611 |
| 2020's | 3 (2.97) | 2.80 |
| Authors | Studies |
|---|---|
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Kurihara, M | 2 |
| Komatsu, H | 2 |
| Sengoku, R | 3 |
| Shibukawa, M | 2 |
| Morimoto, S | 3 |
| Matsubara, T | 2 |
| Arakawa, A | 2 |
| Orita, M | 2 |
| Ishibashi, K | 2 |
| Mitsutake, A | 2 |
| Shibata, S | 2 |
| Ishiura, H | 2 |
| Adachi, K | 2 |
| Ohse, K | 2 |
| Hatano, K | 2 |
| Ihara, R | 2 |
| Higashihara, M | 2 |
| Nishina, Y | 3 |
| Tokumaru, AM | 2 |
| Ishii, K | 2 |
| Saito, Y | 3 |
| Murayama, S | 3 |
| Kanemaru, K | 3 |
| Iwata, A | 2 |
| Maitre, M | 2 |
| Klein, C | 2 |
| Patte-Mensah, C | 2 |
| Mensah-Nyagan, AG | 2 |
| Abdel-Hafiz, L | 1 |
| Müller-Schiffmann, A | 1 |
| Korth, C | 1 |
| Fazari, B | 1 |
| Chao, OY | 1 |
| Nikolaus, S | 1 |
| Schäble, S | 1 |
| Herring, A | 1 |
| Keyvani, K | 1 |
| Lamounier-Zepter, V | 1 |
| Huston, JP | 1 |
| de Souza Silva, MA | 1 |
| Roussel, G | 1 |
| Brun, S | 1 |
| Rusu, C | 1 |
| Vermeiren, Y | 3 |
| Van Dam, D | 3 |
| Aerts, T | 3 |
| Engelborghs, S | 2 |
| De Deyn, PP | 3 |
| Chen, DL | 1 |
| Zhang, P | 1 |
| Lin, L | 1 |
| Zhang, HM | 1 |
| Deng, SD | 1 |
| Wu, ZQ | 1 |
| Ou, S | 1 |
| Liu, SH | 1 |
| Wang, JY | 1 |
| Tajeddinn, W | 2 |
| Persson, T | 1 |
| Maioli, S | 1 |
| Calvo-Garrido, J | 1 |
| Parrado-Fernandez, C | 1 |
| Yoshitake, T | 2 |
| Kehr, J | 2 |
| Francis, P | 1 |
| Winblad, B | 4 |
| Höglund, K | 2 |
| Cedazo-Minguez, A | 2 |
| Aarsland, D | 2 |
| Lin, TW | 1 |
| Liu, YF | 1 |
| Shih, YH | 1 |
| Chen, SJ | 1 |
| Huang, TY | 1 |
| Chang, CY | 1 |
| Lien, CH | 1 |
| Yu, L | 1 |
| Chen, SH | 1 |
| Kuo, YM | 1 |
| Fereshtehnejad, SM | 1 |
| Seed Ahmed, M | 1 |
| Shahnaz, T | 1 |
| Milovanovic, M | 1 |
| Behbahani, H | 1 |
| Jelic, V | 1 |
| Järemo, P | 1 |
| Janssens, J | 1 |
| Martin, JJ | 1 |
| Sieben, A | 1 |
| Takao, M | 1 |
| Hatsuta, H | 1 |
| Komiya, T | 1 |
| Nakano, Y | 1 |
| Uchino, A | 1 |
| Sumikura, H | 1 |
| Wei, Z | 1 |
| Gabriel, GG | 1 |
| Rui, L | 1 |
| Cao, X | 1 |
| Pennington, PR | 1 |
| Chlan-Fourney, J | 1 |
| Nazarali, AJ | 2 |
| Baker, GB | 2 |
| Mousseau, DD | 1 |
| Svennerholm, L | 4 |
| Bråne, G | 2 |
| Karlsson, I | 3 |
| Lekman, A | 2 |
| Ramström, I | 1 |
| Wikkelsö, C | 2 |
| Sjögren, M | 1 |
| Ostling, S | 1 |
| Wallin, A | 2 |
| Blennow, K | 2 |
| Wu, YH | 1 |
| Feenstra, MG | 1 |
| Zhou, JN | 1 |
| Liu, RY | 1 |
| Toranõ, JS | 1 |
| Van Kan, HJ | 1 |
| Fischer, DF | 1 |
| Ravid, R | 1 |
| Swaab, DF | 1 |
| Stuerenburg, HJ | 1 |
| Ganzer, S | 1 |
| Müller-Thomsen, T | 1 |
| Bell, CJ | 1 |
| Hood, SD | 1 |
| Nutt, DJ | 1 |
| Egashira, N | 1 |
| Iwasaki, K | 1 |
| Takashima, A | 1 |
| Watanabe, T | 1 |
| Kawabe, H | 1 |
| Matsuda, T | 1 |
| Mishima, K | 1 |
| Chidori, S | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| van der Cammen, TJ | 1 |
| Tiemeier, H | 1 |
| Engelhart, MJ | 1 |
| Fekkes, D | 1 |
| Crow, TJ | 2 |
| Cross, AJ | 3 |
| Cooper, SJ | 1 |
| Deakin, JF | 1 |
| Ferrier, IN | 2 |
| Johnson, JA | 2 |
| Joseph, MH | 1 |
| Owen, F | 1 |
| Poulter, M | 1 |
| Lofthouse, R | 1 |
| Argentiero, V | 1 |
| Tavolato, B | 1 |
| Soininen, H | 2 |
| MacDonald, E | 1 |
| Rekonen, M | 1 |
| Riekkinen, PJ | 3 |
| Bareggi, SR | 1 |
| Franceschi, M | 1 |
| Bonini, L | 1 |
| Zecca, L | 1 |
| Smirne, S | 1 |
| Wood, PL | 1 |
| Etienne, P | 1 |
| Lal, S | 1 |
| Gauthier, S | 1 |
| Cajal, S | 1 |
| Nair, NP | 1 |
| Gottfries, CG | 5 |
| Adolfsson, R | 3 |
| Aquilonius, SM | 1 |
| Carlsson, A | 1 |
| Eckernäs, SA | 1 |
| Nordberg, A | 1 |
| Oreland, L | 1 |
| Wiberg, A | 1 |
| Bucht, G | 1 |
| Arai, H | 2 |
| Kosaka, K | 2 |
| Iizuka, R | 2 |
| Palmer, AM | 6 |
| Sims, NR | 3 |
| Bowen, DM | 9 |
| Neary, D | 4 |
| Palo, J | 1 |
| Wikstrom, J | 1 |
| Davison, AN | 3 |
| Mena, MA | 1 |
| Aguado, EG | 1 |
| de Yebenes, JG | 1 |
| Losonczy, MF | 1 |
| Mohs, RC | 2 |
| Davis, KL | 2 |
| Bloom, SR | 1 |
| Corsellis, JA | 1 |
| Nybäck, H | 3 |
| Hassan, M | 1 |
| Junthé, T | 1 |
| Ahlin, A | 1 |
| Parnetti, L | 3 |
| Ban, TA | 1 |
| Senin, U | 1 |
| Kumar, AM | 1 |
| Sevush, S | 1 |
| Kumar, M | 1 |
| Ruiz, J | 1 |
| Eisdorfer, C | 1 |
| Francis, PT | 5 |
| Pangalos, MN | 1 |
| Stephens, PH | 1 |
| Bartlett, JR | 1 |
| Bridges, PK | 1 |
| Malizia, AL | 1 |
| Procter, AW | 2 |
| Thomas, DJ | 1 |
| Alhainen, K | 1 |
| Helkala, EL | 2 |
| Reinikainen, K | 1 |
| Riekkinen, P | 1 |
| Chen, CP | 1 |
| Alder, JT | 1 |
| Esiri, MM | 3 |
| McDonald, B | 1 |
| Hope, T | 1 |
| Jobst, KA | 1 |
| Strittmatter, M | 1 |
| Hamann, G | 1 |
| Cramer, H | 2 |
| Reuner, C | 1 |
| Kuntzmann, F | 1 |
| Strubel, D | 1 |
| Wada, H | 1 |
| Seidl, R | 1 |
| Kaehler, ST | 1 |
| Prast, H | 1 |
| Singewald, N | 1 |
| Cairns, N | 1 |
| Gratzer, M | 1 |
| Lubec, G | 1 |
| Davies, P | 1 |
| White, P | 1 |
| Spillane, JA | 1 |
| Goodhardt, MJ | 1 |
| Curzon, G | 1 |
| Iwangoff, P | 1 |
| Meier-Ruge, W | 1 |
| Meyer, JS | 1 |
| Welch, KM | 1 |
| Deshmukh, VD | 1 |
| Perez, FI | 1 |
| Jacob, RH | 1 |
| Haufrect, DB | 1 |
| Mathew, NT | 1 |
| Morrell, RM | 1 |
| Guard, O | 1 |
| Renaud, B | 1 |
| Chazot, G | 1 |
| Siever, L | 1 |
| Kraemer, H | 1 |
| Sack, R | 1 |
| Angwin, P | 1 |
| Berger, P | 1 |
| Zarcone, V | 1 |
| Barchas, J | 1 |
| Brodie, HK | 1 |
| Pomara, N | 2 |
| Stanley, M | 2 |
| LeWitt, PA | 2 |
| Galloway, M | 1 |
| Singh, R | 1 |
| Deptula, D | 2 |
| Reynolds, GP | 3 |
| Strittmatter, MM | 1 |
| Ichimiya, Y | 1 |
| Moroji, T | 1 |
| Yates, CM | 1 |
| Simpson, J | 1 |
| Gordon, A | 1 |
| Lee, S | 1 |
| Chiba, T | 1 |
| Kitahama, T | 1 |
| Kaieda, R | 1 |
| Hagiwara, M | 1 |
| Nagazumi, A | 1 |
| Terashi, A | 1 |
| Kawakatsu, S | 1 |
| Morinobu, S | 1 |
| Shinohara, M | 1 |
| Totsuka, S | 1 |
| Kobashi, K | 1 |
| Nyth, AL | 1 |
| Nakamura, S | 2 |
| Burke, WJ | 1 |
| Park, DH | 1 |
| Chung, HD | 1 |
| Marshall, GL | 1 |
| Haring, JH | 1 |
| Joh, TH | 1 |
| Malm, J | 1 |
| Kristensen, B | 1 |
| Ekstedt, J | 1 |
| Wester, P | 1 |
| Zubenko, GS | 1 |
| Moossy, J | 1 |
| Martinez, AJ | 1 |
| Rao, G | 1 |
| Claassen, D | 1 |
| Rosen, J | 1 |
| Kopp, U | 1 |
| Martignoni, E | 1 |
| Bono, G | 1 |
| Blandini, F | 1 |
| Sinforiani, E | 1 |
| Merlo, P | 1 |
| Nappi, G | 1 |
| Molchan, SE | 3 |
| Hill, JL | 2 |
| Mellow, AM | 3 |
| Lawlor, BA | 3 |
| Martinez, R | 1 |
| Sunderland, T | 5 |
| Martinez, RA | 2 |
| Davis, CL | 1 |
| Rubinow, DR | 1 |
| Berrettini, WH | 1 |
| Vitiello, B | 1 |
| Tariot, PN | 2 |
| Cohen, RM | 2 |
| Nyman, H | 2 |
| Blomqvist, G | 1 |
| Sjögren, I | 1 |
| Stone-Elander, S | 1 |
| Perry, EK | 1 |
| McKeith, I | 1 |
| Thompson, P | 1 |
| Marshall, E | 1 |
| Kerwin, J | 1 |
| Jabeen, S | 1 |
| Edwardson, JA | 1 |
| Ince, P | 1 |
| Blessed, G | 1 |
| Irving, D | 1 |
| Liu, HC | 1 |
| Yang, JC | 1 |
| Chang, YF | 1 |
| Liu, TY | 1 |
| Chi, CW | 1 |
| Seeldrayers, P | 1 |
| Messina, D | 1 |
| Desmedt, D | 1 |
| Dalesio, O | 1 |
| Hildebrand, J | 1 |
| Cutler, NR | 2 |
| Haxby, J | 1 |
| Kay, AD | 3 |
| Narang, PK | 1 |
| Lesko, LJ | 1 |
| Costa, JL | 1 |
| Ninos, M | 1 |
| Linnoila, M | 1 |
| Potter, WZ | 2 |
| Renfrew, JW | 1 |
| Davis, BM | 1 |
| Greenwald, BS | 1 |
| Mathé, AA | 1 |
| Johns, CA | 1 |
| Horvath, TB | 1 |
| Volicer, L | 3 |
| Langlais, PJ | 1 |
| Matson, WR | 1 |
| Mark, KA | 1 |
| Gamache, PH | 1 |
| Middlemiss, DN | 1 |
| Edel, N | 1 |
| Degrell, I | 1 |
| Pék, G | 1 |
| Nagy, D | 1 |
| Nagy, E | 1 |
| Hoyer, S | 1 |
| Sparks, DL | 1 |
| Markesbery, WR | 1 |
| Slevin, JT | 1 |
| Milstien, S | 3 |
| Kaufman, S | 3 |
| Creasey, H | 1 |
| Haxby, JV | 1 |
| Rapoport, SI | 2 |
| Benton, JS | 1 |
| Mann, DM | 1 |
| Snowden, JS | 2 |
| Wilcock, GK | 2 |
| Newhouse, PA | 1 |
| Mueller, EA | 1 |
| Murphy, DL | 1 |
| Mayeux, R | 2 |
| Stern, Y | 2 |
| Sano, M | 2 |
| Cote, L | 2 |
| Williams, JB | 1 |
| Gottfries, J | 1 |
| Långström, G | 1 |
| Godridge, H | 1 |
| Czudek, C | 1 |
| Calcutt, NA | 1 |
| Benton, M | 1 |
| Risby, ED | 1 |
| Hsiao, JK | 1 |
| Agren, H | 1 |
| Rudorfer, MV | 1 |
| Schalling, D | 1 |
| Kaye, JA | 2 |
| May, C | 2 |
| Daly, E | 2 |
| Atack, JR | 2 |
| Sweeney, DJ | 1 |
| Luxenberg, JS | 1 |
| Friedland, RP | 2 |
| Koyama, E | 1 |
| Minegishi, A | 1 |
| Ishizaki, T | 1 |
| Reinikainen, KJ | 1 |
| Paljärvi, L | 1 |
| Huuskonen, M | 1 |
| Laakso, M | 1 |
| Stratmann, GC | 1 |
| Freed, DM | 1 |
| Corkin, S | 1 |
| Growdon, JH | 2 |
| Nissen, MJ | 1 |
| Sweeney, DL | 1 |
| Beal, MF | 1 |
| Jolkkonen, J | 1 |
| Kutvonen, R | 1 |
| Lehtinen, M | 1 |
| Singh, RR | 1 |
| Bissette, G | 1 |
| Nemeroff, CB | 1 |
| Corona, GL | 1 |
| Cucchi, ML | 1 |
| Frattini, P | 1 |
| Santagostino, G | 1 |
| Schinelli, S | 1 |
| Romani, A | 1 |
| Pola, A | 1 |
| Zerbi, F | 1 |
| Savoldi, F | 1 |
| Williams, J | 1 |
| Rosenstein, R | 1 |
| Fukuda, H | 1 |
| Hara, K | 1 |
| Udaka, F | 1 |
| Kameyama, M | 1 |
| Chen, JC | 1 |
| Crino, PB | 1 |
| Vogt, BA | 1 |
| Fishman, J | 1 |
| Rubins, J | 1 |
| Schenepper, PW | 1 |
| Wolfe, N | 1 |
| Direnfeld, LK | 1 |
| Freedman, M | 1 |
| Albert, ML | 1 |
| Langlias, PJ | 1 |
| Bird, ED | 1 |
| Gibson, CJ | 1 |
| Logue, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Kinetic Studies in Whole Body and Brain of [11C]DASB PET Imaging of Serotonin Transporters[NCT00059046] | 20 participants | Observational | 2003-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for hydroxyindoleacetic acid and Alzheimer Disease
| Article | Year |
|---|---|
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Tryptophan metabolites modify brain Aβ peptide degradation: A role in Alzheimer's disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Neprilys | 2020 |
Acute tryptophan depletion. Part II: clinical effects and implications.
Topics: Alleles; Alzheimer Disease; Autistic Disorder; Bipolar Disorder; Cognitive Behavioral Therapy; Depre | 2005 |
Serotonin in Alzheimer-type dementia and other dementing illnesses.
Topics: Alzheimer Disease; Dementia; Humans; Hydroxyindoleacetic Acid; Kinetics; Receptors, Cell Surface; Re | 1990 |
Senile dementia and presenile dementia.
Topics: Acetylcholinesterase; Alzheimer Disease; Arginine Vasopressin; Biopterins; Brain Chemistry; Cerebral | 1990 |
The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines.
Topics: Aged; Alzheimer Disease; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydr | 1990 |
Neurotoxic properties of a serotonin oxidation product: possible role in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Brain Chemistry; Humans; Hydroxyindoleacetic Acid; Indolequinones | 1989 |
8 trials available for hydroxyindoleacetic acid and Alzheimer Disease
| Article | Year |
|---|---|
Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Female; G(M1) Ganglioside; Homovanillic Acid; | 2002 |
Clinical experiences and biochemical findings with tacrine (THA).
Topics: Administration, Rectal; Alzheimer Disease; Biogenic Monoamines; Cross-Sectional Studies; Double-Blin | 1993 |
Peripheral serotonin in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Female; Humans; Hydroxyindoleacetic Aci | 1995 |
Neurochemical parameters in senile dementia of the Alzheimer type. A longitudinal study in four cases.
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Brain Chemistry; Homovanillic Acid; | 1996 |
The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Citalopram; Dementia, Multi-Infarct; Double-Blind Metho | 1990 |
Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
Topics: Aged; Alzheimer Disease; Biogenic Monoamines; Cognition; Dopamine; Double-Blind Method; Epinephrine; | 1991 |
Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures.
Topics: Aged; Alzheimer Disease; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Homovanilli | 1985 |
Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arousal; Blood Pressure; Choline; Clinical Trials as Top | 1989 |
86 other studies available for hydroxyindoleacetic acid and Alzheimer Disease
| Article | Year |
|---|---|
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Frontotemporal Dementia; Humans; Hydroxyindole | 2023 |
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Frontotemporal Dementia; Humans; Hydroxyindole | 2023 |
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Frontotemporal Dementia; Humans; Hydroxyindole | 2023 |
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Frontotemporal Dementia; Humans; Hydroxyindole | 2023 |
Aβ dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Be | 2018 |
5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer's disease.
Topics: 5-Hydroxytryptophan; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anima | 2018 |
Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Biogenic Monoam | 2014 |
Protective effects of bajijiasu in a rat model of Aβ₂₅₋₃₅-induced neurotoxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Biogenic Monoamines; Brain; Cat | 2014 |
Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Brain; Chromatography, High Pressure Liquid; | 2014 |
5-HT1B and other related serotonergic proteins are altered in APPswe mutation.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Annexin A2; Cell Line, Tumor; Female; Hi | 2015 |
Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amygdala; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain-D | 2015 |
Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blood Platelets; Chromatography, High Pressure Liquid; Cog | 2016 |
Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Brain; Dopamine; Female; Frontotemporal Dementia; Humans; Hydroxyindoleacet | 2016 |
Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Autopsy; Biomarkers; Diagn | 2017 |
Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Cells, Cultured; Cerebral Cortex; Chromatography, | 2012 |
Biological correlates of clinical subgroups of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Biomarkers; Brain; | 2002 |
Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Circadian Rhythm; Dopamine; Humans; Hydroxyindoleacet | 2003 |
5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Depression; Dopamine; Female; Homovanillic Acid; Human | 2004 |
Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain Chemistry; Depressive Disorder; Disease Models, | 2005 |
Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Case-Control Studies; Delirium; Female; Hom | 2006 |
Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides.
Topics: Aged; Aging; Alzheimer Disease; Binding, Competitive; Biogenic Amines; Brain; Choline O-Acetyltransf | 1984 |
Dopamine (DA) and serotonin metabolic levels in the cerebrospinal fluid (CSF) in Alzheimer's presenile dementia under basic conditions and after stimulation with cerebral cortex phospholipids (BC-PL).
Topics: Alzheimer Disease; Cerebral Cortex; Dementia; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacet | 1980 |
Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
Topics: Aged; Alzheimer Disease; Butyrophenones; Dementia; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1981 |
Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications?
Topics: Age Factors; Aged; Aging; Alzheimer Disease; Brain Chemistry; Dementia; Female; gamma-Aminobutyric A | 1982 |
Reduced lumbar CSF somatostatin levels in Alzheimer's disease.
Topics: Aged; Alcohol Amnestic Disorder; Alzheimer Disease; Dementia; Female; Homovanillic Acid; Humans; Hyd | 1982 |
Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).
Topics: Aged; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Female; Gangliosides; Homovanillic Acid | 1983 |
Dementia of the Alzheimer type and multi-infarct dementia: a clinical description and diagnostic problems.
Topics: Aged; Alzheimer Disease; Blood Chemical Analysis; Cardiovascular Diseases; Dementia; Diagnosis, Diff | 1984 |
Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia.
Topics: Alzheimer Disease; Biogenic Amines; Brain; Dopamine; Humans; Hydroxyindoleacetic Acid; Norepinephrin | 1984 |
Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Brain; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 1984 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations.
Topics: Adult; Alzheimer Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxy | 1984 |
Serotonin receptor changes in dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Choline O-Acetyltransferase; Female; Humans; Hydroxyindoleacetic Acid; Keta | 1984 |
Glycosaminoglycan polysulfate in primary degenerative dementia. Pilot study of biologic and clinical effects.
Topics: Aged; Alzheimer Disease; Blood Platelets; Female; Glycosaminoglycans; Homovanillic Acid; Humans; Hyd | 1995 |
Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression.
Topics: Adult; Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Cerebral Ventricles; Female; | 1993 |
The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Biogenic Monoamines; Female; | 1993 |
Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication.
Topics: Age Factors; Alzheimer Disease; Antipsychotic Agents; Behavior; Biomarkers; Depression; Female; Huma | 1996 |
Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio.
Topics: Aged; Aged, 80 and over; Albumins; alpha 1-Antichymotrypsin; Alzheimer Disease; Blood-Brain Barrier; | 1998 |
Serotonin (5-HT) in brains of adult patients with Down syndrome.
Topics: Adult; Alzheimer Disease; Brain; Caudate Nucleus; Cerebellum; Chromatography, High Pressure Liquid; | 1999 |
Biochemical changes in Alzheimer's disease-senile dementia: neurotransmitters in senile dementia of the Alzheimer's type.
Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Choline O-Acetyltransferase; De | 1979 |
Accelerated ageing or selective neuronal loss as an important cause of dementia?
Topics: Aged; Aging; Alzheimer Disease; Atrophy; Caudate Nucleus; Cell Count; Choline O-Acetyltransferase; D | 1979 |
Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease.
Topics: 5-Hydroxytryptophan; Aged; Alzheimer Disease; Carbidopa; Dementia; Dopamine; Drug Combinations; Fema | 1977 |
[Cerebral metabolism of dopamine and of serotonin during Alzheimer and Pick's diseases. Dynamic study by the test using probenecid].
Topics: Aged; Alzheimer Disease; Brain Chemistry; Dementia; Dopamine; Female; Homovanillic Acid; Humans; Hyd | 1976 |
Gradients of biogenic amine metabolites in cerebrospinal fluid.
Topics: Alzheimer Disease; Amphetamine; Brain Diseases; Brain Neoplasms; Depression; Homovanillic Acid; Huma | 1975 |
Increased CSF HVA response to arecoline challenge in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Arecoline; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1992 |
Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Brain Chemistry; Caudate Nucleus; Dementia; Do | 1992 |
Parkinson's disease and dementia: clinical and neurochemical correlations.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1992 |
Neurotransmitter changes in early- and late-onset Alzheimer-type dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Brain Chemistry; Choline O-Acetyltransferase; Hom | 1992 |
5-Hydroxytryptamine and dopamine in pre-senile and senile Alzheimer-type dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Amygdala; Brain; Caudate Nucleus; Dopamine; Homovanillic Acid; | 1990 |
CSF beta-endorphin, HVA and 5-HIAA of dementia of the Alzheimer type and Binswanger's disease in the elderly.
Topics: Alzheimer Disease; beta-Endorphin; Dementia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1990 |
Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Adult; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Cerebral Ventric | 1990 |
Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Axons; Humans; Hydroxyindoleacetic Acid; Male; | 1990 |
CSF monoamine metabolites, cholinesterases and lactate in the adult hydrocephalus syndrome (normal pressure hydrocephalus) related to CSF hydrodynamic parameters.
Topics: Aged; Alzheimer Disease; Cerebrospinal Fluid Pressure; Cholinesterases; Dementia, Multi-Infarct; Fem | 1991 |
Neuropathologic and neurochemical correlates of psychosis in primary dementia.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Female; Humans; Hydroxyindoleacetic Acid; Male; Neurofibri | 1991 |
CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
Topics: Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Female; Homovanillic Acid; Hu | 1991 |
Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Depressive Disorder; Dynorphins; Female; Galanin; Homovanillic Acid; | 1991 |
Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects.
Topics: Aged; Alzheimer Disease; Blood Glucose; Brain; Brain Mapping; Cerebral Cortex; Deoxyglucose; Dominan | 1991 |
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Hallucinatio | 1991 |
Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; China; Chromatography, High Pressure Liquid; Dihy | 1991 |
CSF levels of neurotransmitters in Alzheimer-type dementia. Effects of ergoloid mesylate.
Topics: Aged; Alzheimer Disease; Dihydroergotoxine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1985 |
Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Choline; Choline Deficiency; Cognition; Female; Gas C | 1985 |
Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid.
Topics: 5-Hydroxytryptophan; Aged; Alzheimer Disease; Dementia; Humans; Hydroxyindoleacetic Acid; Middle Age | 1985 |
Binding of the novel serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin in normal and Alzheimer brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alzheimer Disease; Binding Sites; Brain; Cerebral Cortex; Fr | 1986 |
Dementias, psychological tests, and neurotransmitters.
Topics: Aged; Alcoholism; Alzheimer Disease; Dementia; Diagnosis, Differential; Female; Homovanillic Acid; H | 1985 |
Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis.
Topics: Aged; Alzheimer Disease; Basal Ganglia; Biogenic Amines; Dopamine; Homovanillic Acid; Humans; Hydrox | 1986 |
Cerebrospinal fluid biopterin is decreased in Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Biopterins; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindo | 1986 |
Presynaptic serotonergic dysfunction in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Frontal Lobe; Glucose; Humans; Hydroxyindoleacetic Acid; Neurofibrils; Pot | 1987 |
Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Biogenic Amines; | 1987 |
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Biogenic Amines; Dose-Response Relationship, Drug; Homovanillic Acid; Huma | 1987 |
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.
Topics: Aged; Alzheimer Disease; Arousal; Attention; Biogenic Amines; Cognition Disorders; Homovanillic Acid | 1987 |
Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography and gas chromatography-mass spectrometry.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biogenic Amines; Chromatography, High Pressure Liquid; G | 1987 |
Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.
Topics: Acetylcholine; Adult; Age Factors; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Dopamine; | 1987 |
The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio.
Topics: Alzheimer Disease; Antidepressive Agents; Cerebrospinal Fluid; Depressive Disorder; Drug Evaluation; | 1987 |
Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1987 |
Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features.
Topics: Aged; Alzheimer Disease; Biopterins; Dementia; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1988 |
Simultaneous determination of four monoamine metabolites and serotonin in cerebrospinal fluid by "high-performance" liquid chromatography with electrochemical detection; application for patients with Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Electrochem | 1988 |
A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Female; gamma-Aminob | 1988 |
Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; gamma-Aminobutyric Acid; | 1988 |
Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
Topics: Aged; Alzheimer Disease; Attention; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1988 |
Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Analysis of Variance; Biopterins; Female; Homovanilli | 1988 |
Vasopressin levels in CSF of Alzheimer patients: correlations with monoamine metabolites and neuropsychological test performance.
Topics: Aged; Alzheimer Disease; Arginine Vasopressin; Female; Glycols; Homovanillic Acid; Humans; Hydroxyin | 1989 |
Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biogenic Amines; Female; Hippocampus; Humans; Hydroxyind | 1989 |
Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.
Topics: Aged; Alzheimer Disease; Behavior; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1989 |
CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites.
Topics: Aged; Alzheimer Disease; Corticotropin-Releasing Hormone; Disability Evaluation; Female; Homovanilli | 1989 |
Coexisting dementia and depression in Parkinson's disease.
Topics: Aged; Aging; Alzheimer Disease; Dementia; Depression; Humans; Hydroxyindoleacetic Acid; Middle Aged; | 1989 |
[Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases].
Topics: Adult; Aged; Alzheimer Disease; Brain Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxyin | 1989 |
Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type.
Topics: Aged; Alzheimer Disease; Dementia; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Serotonin | 1985 |
Neurotransmitters in the brains of patients with dementia disorders.
Topics: Acetylcholine; Aged; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Dementia; Dopamine; Glut | 1985 |
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
Topics: Adult; Aged; Alzheimer Disease; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 1985 |
Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.
Topics: Acetylcholine; Age Factors; Aged; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Cholinergic | 1985 |